Factors influencing adrenocortical suppression during long-term triamcinolone acetonide therapy in asthma.
The causes for an abnormal five-hour tetracosactrin test in 14 out of 75 patients (18.5% of the entire group), treated continuously with triamcinolone acetonide long-term (mean 3.2 years) for asthma or related syndromes, were investigated. The average daily dosage, duration of treatment and age of the patients were analyzed. Statistical analysis indicated that the risk of adrenocortical suppression was increased by the patient's age and the average patients under the age of 50, receiving less than 1.2 mg triamcinolone acetonide daily, only rarely develop adrenocortical functional impairment.
D000302:Adrenal Cortex / Q000187:drug effects*; D000304:Adrenal Cortex Function Tests; D000328:Adult; D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D002417:Cattle; D003366:Cosyntropin; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*
D003366:Cosyntropin; D014222:Triamcinolone Acetonide; D006854:Hydrocortisone